Key facts
- Tajiri’s last known valuation is $145.6M (Apr 2020).
- It has raised $85.8M; the latest was Secondary Transaction - Private in Sep 2025.
- Notable investors include Shenzhen Capital Group, Oriental Fortune Capital, CDH Investments, SEEDS Capital, Hongtai Capital Holdings — 12 tracked in total.
- Status: Privately Held (backing).
Investors
12+- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Tajiri
- ·The full record, as it builds
Funding rounds
No funding rounds for Tajiri are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tajiri
Developer of anti-cancer medical solutions intended to address drug resistance and urgent clinical needs through next-generation small-molecule therapies. The company offers drug resistance in cancer treatment and innovative medicines for more effective cancer treatment, thereby enabling them to overcome resistance to existing therapies, reduce treatment toxicity, and achieve more effective cancer management.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2014
- Employees
- 72
- Website
- tjrbiosciences.com/
- Ownership
- Privately Held (backing)
Tajiri doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tajiri shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tajiri in its N-PORT filings yet. We sweep new filings monthly.